Trial · NCT00687297

Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer

NCT00687297, Phase 2, Completed, PrECOG, LLC.; results first posted 2012-07-10

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer. Trials, record NCT00687297. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00687297

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
NCT number: NCT00687297
Status: Completed
Phases: Phase 2
Enrollment: 162 participants, actual
Lead sponsor: PrECOG, LLC.
Conditions: Lung Cancer, Non Small Cell Lung Cancer
Interventions: vandetanib induction, Docetaxel, Carboplatin, Placebo, Vandetanib maintenance
First posted: 2008-05-30
Last updated: 2018-05-30
Results first posted: 2012-07-10

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Progression-free Survival	Assessed every 2 cycles (1 cycle = 3 weeks during induction and 4 weeks during maintenance))	Time from randomization (prior to induction) to first evidence of disease progression or death without progression. Participants alive without progression were censored at the date of last disease evaluation.
Secondary	Objective Response Rate	Assessed every 2 cycles (1 cycle = 3 weeks during induction and 4 weeks during maintenance))	Best overall response (complete or partial response), assessed using RECIST criteria (version 1.0)
Secondary	Progression-free Survival	every 2 cycles (every 6 weeks during induction, every 8 weeks during maintenance)	Time from randomization to first evidence of disease progression or death. Patients alive without progression are censored at the date of last disease evaluation.

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Progression-free Survival	Assessed every 2 cycles (1 cycle = 3 weeks during induction and 4 weeks during maintenance))	All randomized patients were included.	Months	MEDIAN
SECONDARY	Objective Response Rate	Assessed every 2 cycles (1 cycle = 3 weeks during induction and 4 weeks during maintenance))	All randomized patients were included.	percentage of participants	NUMBER
SECONDARY	Progression-free Survival	every 2 cycles (every 6 weeks during induction, every 8 weeks during maintenance)	All randomized patients were included.	months	MEDIAN

Source ClinicalTrials.gov

Results by group5

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Progression-free Survival	All Randomized Patients	4.5	95% Confidence Interval 3.6 to 4.9	Months
Objective Response Rate	Randomized to Vandetanib Maintenance	18.8	95% Confidence Interval 10.9 to 29.0	percentage of participants
Objective Response Rate	Randomized to Placebo Maintenance	18.3	95% Confidence Interval 10.6 to 28.4	percentage of participants
Progression-free Survival	Randomized to Vandetanib Maintenance	4.5	95% Confidence Interval 3.3 to 5.8	months
Progression-free Survival	Randomized to Placebo Maintenance	4.2	95% Confidence Interval 2.8 to 4.9	months

Source ClinicalTrials.gov

Participant flow18

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Randomization	STARTED	Randomized to Vandetanib Maintenance	80
Randomization	STARTED	Randomized to Placebo Maintenance	82
Randomization	COMPLETED	Randomized to Vandetanib Maintenance	77
Randomization	COMPLETED	Randomized to Placebo Maintenance	81
Randomization	NOT COMPLETED	Randomized to Vandetanib Maintenance	3
Randomization	NOT COMPLETED	Randomized to Placebo Maintenance	1
Induction	STARTED	Randomized to Vandetanib Maintenance	77
Induction	STARTED	Randomized to Placebo Maintenance	81
Induction	COMPLETED	Randomized to Vandetanib Maintenance	32
Induction	COMPLETED	Randomized to Placebo Maintenance	26

1 to 10 of 18Source ClinicalTrials.gov

See all 18 participant flow

Adverse events357

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Abdomen, Pain	Gastrointestinal disorders	Treated on Vandetanib Maintenance	3	32
other	Abdomen, Pain	Gastrointestinal disorders	Treated on Placebo Maintenance	0	26
other	Abdomen, Pain	Gastrointestinal disorders	All Treated Patients - Induction	7	157
other	Alopecia	Skin and subcutaneous tissue disorders	Treated on Vandetanib Maintenance	8	32
other	Alopecia	Skin and subcutaneous tissue disorders	Treated on Placebo Maintenance	4	26
other	Alopecia	Skin and subcutaneous tissue disorders	All Treated Patients - Induction	50	157
other	Anorexia	Metabolism and nutrition disorders	Treated on Vandetanib Maintenance	6	32
other	Anorexia	Metabolism and nutrition disorders	Treated on Placebo Maintenance	3	26
other	Anorexia	Metabolism and nutrition disorders	All Treated Patients - Induction	27	157
other	Back, pain	Musculoskeletal and connective tissue disorders	Treated on Vandetanib Maintenance	0	32

1 to 10 of 357Source ClinicalTrials.gov

See all 357 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Treated on Vandetanib Maintenance
Total, all-cause mortality	Treated on Placebo Maintenance
Total, all-cause mortality	All Treated Patients - Induction
Total, other adverse events	Treated on Vandetanib Maintenance	29	32
Total, other adverse events	Treated on Placebo Maintenance	22	26
Total, other adverse events	All Treated Patients - Induction	145	157
Total, serious adverse events	Treated on Vandetanib Maintenance	22	32
Total, serious adverse events	Treated on Placebo Maintenance	11	26
Total, serious adverse events	All Treated Patients - Induction	111	157

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
23689430	RESULT

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00687297

GET https://conductscience.org/api/trials/v1/NCT00687297/events?page=2

API reference For AI assistants